Complex diseases affect us all. Illumina is committed to advancing our understanding of complex diseases and how they will be diagnosed and treated.
Complex diseases result from a combination of genetic and environmental factors, many of which are not understood. These diseases include neurodegenerative, psychiatric, and autoimmune disorders, and others.
The expanding Illumina complex disease product portfolio includes array and next-generation sequencing (NGS) technologies that are helping drive a revolution in complex disease genomics. These solutions deliver high-quality, reproducible results that accelerate research on various complex diseases. These discoveries have the potential to lead to life-changing improvements for patients and their loved ones.
Researchers perform genome-wide association studies to identify disease-associated DNA risk loci and develop scores for clinical validation.Read Article
Integrating imaging, multiomic technologies, and big data uncovers novel diagnostic and therapeutic targets for chronic diseases.Read Article
Neuroscience researchers are using NGS to identify variants for a new sequencing array designed for ADHD, autism, and schizophrenia studies.Read Article
This review gives a general overview of how genomic technologies and NGS can help in the study of complex diseases, and highlights recent publications featuring Illumina technology.Read Publication Review